| 4.63 0.805 (21.05%) | 09-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.47 | 1-year : | 6.36 |
| Resists | First : | 4.68 | Second : | 5.44 |
| Pivot price | 4.02 |
|||
| Supports | First : | 3.46 | Second : | 2.87 |
| MAs | MA(5) : | 3.86 |
MA(20) : | 4.13 |
| MA(100) : | 4.58 |
MA(250) : | 6.35 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 13.3 |
D(3) : | 21.4 |
| RSI | RSI(14): 41  |
|||
| 52-week | High : | 13.19 | Low : | 3.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GLMD ] has closed above bottom band by 15.0%. Bollinger Bands are 15.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.8 - 3.82 | 3.82 - 3.83 |
| Low: | 3.52 - 3.54 | 3.54 - 3.56 |
| Close: | 3.6 - 3.63 | 3.63 - 3.65 |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Fri, 02 Oct 2026
Galmed Pharmaceuticals Ltd (OTC: GLMD) Share Price, GLMD Stock News, GLMD Share Price & Updates - kalkine.ca
Fri, 11 Sep 2026
Eocene (Nasdaq:EOCN) - Stock Analysis - Simply Wall Street
Thu, 10 Sep 2026
EOCN Stock Price and Chart — NASDAQ:EOCN - TradingView
Wed, 09 Sep 2026
Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation - PR Newswire
Thu, 03 Sep 2026
Galmed Pharmaceuticals: Q2 Earnings Snapshot - KTVB
Thu, 03 Sep 2026
Galmed Pharmaceuticals: Q2 Earnings Snapshot - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 1.8 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 4 (K) |
| EPS | -14.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.9 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.2 % |
| Return on Equity (ttm) | -68.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.26 |
| PEG Ratio | 0 |
| Price to Book value | 0.21 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|